Publications en collaboration avec des chercheurs de University of Toronto (1)

2023

  1. Results from part A of the multi-center, double-blind, randomized, placebo-controlled NefIgArd trial, which evaluated targeted-release formulation of budesonide for the treatment of primary immunoglobulin A nephropathy

    Kidney International, Vol. 103, Núm. 2, pp. 391-402